Baxter Intl Inc Stock Price, News & Analysis

Baxter International (NYSE: BAX) has announced a quarterly cash dividend of $0.17 per share of common stock. The dividend will be paid on July 1, 2025, to stockholders of record as of May 30, 2025. Based on this quarterly distribution, the indicated annual dividend rate for Baxter shareholders stands at $0.68 per share of common stock.

Baxter International (NYSE:BAX) reported strong Q1 2025 results, with sales from continuing operations reaching $2.63 billion, up 5% on both reported and operational basis. The company posted U.S. GAAP EPS of $0.13 and adjusted EPS of $0.55, exceeding previous guidance. U.S. sales grew 11% to $1.49 billion, while international sales reached $1.14 billion. All three segments showed growth: Medical Products & Therapies ($1.26B, +3%), Healthcare Systems & Technologies ($704M, +6%), and Pharmaceuticals ($581M, +1%). Following these results, Baxter raised the bottom end of its full-year 2025 adjusted EPS guidance to $2.47-$2.55 and expects sales growth of 7-8% on a reported basis.

The company recently launched Voalte Linq device with voice-activation technology and introduced room-temperature storage Hemopatch Sealing Hemostat in Europe.

Baxter, a global medtech leader, has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time.

Joel Grade, Baxter's chief financial officer, will be representing the company at the conference. Interested parties can access the live webcast through www.baxter.com. The presentation recording will remain available for replay until Sunday, November 9, 2025.

Baxter International (NYSE:BAX), a global medtech leader, has announced it will host a conference call to discuss its first-quarter 2025 financial results. The call is scheduled for Thursday, May 1, 2025, at 7:30 a.m. Central Time. Investors can pre-register for the call through a provided registration link. The conference call will also be accessible via webcast through Baxter's website.

Baxter International Inc. (NYSE:BAX) has announced the launch of an enhanced version of Hemopatch Sealing Hemostat that can now be stored at room temperature in Europe. This evolution eliminates the need for refrigeration, making the product more accessible in operating rooms for immediate use during critical situations.

Hemopatch Sealing Hemostat is a ready-to-use absorbable collagen pad designed for tissue sealing, dura sealing, and hemostasis in both open and minimally invasive surgeries. The product consists of a soft, flexible collagen pad derived from bovine dermis, coated with NHS-PEG, and features blue squares on the non-coated side for differentiation.

According to real-world data across Europe, the product has demonstrated effectiveness in achieving rapid and sustainable hemostasis across various surgical specialties. This product enhancement is a result of collaboration between surgeons and Baxter, addressing the critical need for immediate access during surgical procedures.

Baxter International (NYSE:BAX) has announced its 2025 Annual Meeting of Stockholders will be held virtually on Tuesday, May 6, 2025 at 9 a.m. Central Time. The virtual format aims to provide accessible, safe, and cost-effective participation for all stockholders.

Stockholders of record can attend by accessing virtualshareholdermeeting.com/BAX2025 with their 16-digit control number. Questions can be submitted either before the meeting (April 22-May 5) through proxyvote.com or live during the event. Voting options include pre-meeting methods outlined in proxy materials or electronic voting during the meeting.

The meeting will also be accessible to guests in listen-only mode, though they won't have voting or question-asking privileges. Online access opens at 8:45 a.m. Central Time, and stockholders holding shares in 'street name' should follow their broker's instructions for attendance.

Baxter International (NYSE:BAX) unveiled its first voice-activated technology, the Voalte Linq device powered by Scotty assistant, at HIMSS25. This lightweight, wearable badge integrates with Baxter's connected care portfolio, including Voalte Mobile and Voalte Nurse Call systems.

The technology aims to streamline hospital communication through voice commands activated by saying 'Hey Scotty.' Key benefits include:

• Enhanced communication efficiency between care teams
• Integration with existing Baxter solutions for automated workflows
• Support for patient and staff safety through rapid response capabilities

The device addresses communication challenges in healthcare settings, where over 60% of sentinel events are caused by communication failures according to the Joint Commission. Voalte Linq will be available in the U.S. in the second half of 2025, supporting both facility-wide and unit-specific communication in areas such as Operating Room, Emergency Department, and Labor and Delivery.

Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the Barclays 27th Annual Global Healthcare Conference. Joel Grade, Baxter's chief financial officer, will deliver a presentation on Wednesday, March 12, 2025 at 1:00 p.m. Eastern Time.

The presentation will be accessible through a live webcast on www.baxter.com. Interested parties can access the replay of the presentation through Monday, September 8, 2025.

Baxter International (BAX) reported Q4 2024 sales from continuing operations of $2.75 billion, up 1% reported and 2% on constant currency, exceeding guidance. Q4 U.S. GAAP diluted EPS loss was ($0.95), with adjusted EPS of $0.58 from continuing operations.

Full-year 2024 sales reached $10.64 billion, increasing 3% on both reported and constant currency basis. The company completed the sale of its Kidney Care business to Carlyle for approximately $3.4 billion in net after-tax proceeds, exceeding previous expectations of $3.15-3.25 billion.

For 2025 outlook, Baxter expects sales growth from continuing operations of 5-6% reported, and 4-5% operational. The company projects adjusted earnings from continuing operations of $2.45-2.55 per diluted share for full-year 2025.